ArticleArchives of toxicology2026
Cylindrospermopsin toxicokinetics: in silico ADMET modeling, rat and human liver microsome metabolism, and UHPLC-MS/MS metabolite characterization.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cylindrospermopsin is a potent cyanobacterial toxin of growing global concern due to its environmental persistence and broad toxicological profile. Despite increasing evidence of its toxic effects, knowledge of its toxicokinetics remains limited. This study integrates in silico ADMET predictions with in vitro microsomal assays using human and sex-stratified rat liver microsomes to characterize CYN biotransformation. In silico predictions indicated low intestinal absorption, improbable blood-brain barrier (BBB) penetration, minimal binding to plasma proteins, and very limited CYP450-mediated metabolism. However, several potential phase II conjugation routes were identified, with certain metabolites predicted to display altered toxicological properties compared with the parent compound. Complementary in vitro studies in microsomes confirmed the high metabolic stability of CYN, with only modest decreases in toxin concentration observed during incubation (8-15% decrease). Notably, biotransformation was more evident under phase II conditions, particularly glucuronidation and amino acid conjugation. Novel metabolites were detected for the first time by Ultra-High Performance Liquid Chromatography (UHPLC-/MS/MS), including conjugates with cysteine, glycine, taurine, and arginine, as well as with fatty acids. No significant quantitative differences were observed between sexes or species, although qualitative variability in metabolite profiles was detected. These findings provide new insights into the metabolic fate of CYN, underscore the importance of conjugation reactions in its detoxification, and support the application of integrative computational and experimental approaches to improve cyanotoxin risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.